Caffeine and Progression of Parkinson Disease
- 1 July 2008
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 31 (4) , 189-196
- https://doi.org/10.1097/wnf.0b013e31815a3f03
Abstract
Objective: Caffeine use is negatively associated with the risk of developing Parkinson disease (PD) and is protective in animal models of PD, but the relationship between caffeine intake and rate of progression of PD is unknown. We assessed this relationship using data from 2 recent clinical trials of PD. Methods: Data were ascertained from 2 recent 1-year clinical trials that together included 413 early PD subjects who did not require symptomatic therapy at the time of study entry. Exploratory analyses compared caffeine intake with rate of progression of PD, as measured by either the likelihood of progression to the point of requiring symptomatic therapy or by change in the total Unified Parkinson Disease Rating Scale score. Results: Rate of progression of PD did not differ significantly between those in the highest and lowest quartiles for caffeine use for either of the primary measures or for secondary analyses of changes in scores on the motor or activities of daily living subsections of the Unified Parkinson Disease Rating Scale. Other secondary analyses yielded variable results. Conclusions: These data do not reveal a consistent relationship between caffeine intake and rate of progression of PD by these measures, although a larger study is required for sufficient power to more fully assess this relationship.Keywords
This publication has 18 references indexed in Scilit:
- A randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson diseaseNeurology, 2007
- A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson diseaseNeurology, 2006
- Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2005
- A responsive outcome for Parkinson's disease neuroprotection futility studiesAnnals of Neurology, 2005
- Adenosine A2A Receptor Antagonists for Parkinson???s DiseaseDrugs & Aging, 2005
- Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's diseasePublished by Elsevier ,2004
- Neuroprotection by caffeine and more specific A 2A receptor antagonists in animal models of Parkinson’s diseaseNeurology, 2003
- Randomized trial of the adenosine A 2A receptor antagonist istradefylline in advanced PDNeurology, 2003
- Caffeinated clues and the promise of adenosine A 2A antagonists in PDNeurology, 2002
- Opposite actions of caffeine and creatine on muscle relaxation time in humansJournal of Applied Physiology, 2002